BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29719024)

  • 1. Molecular advances in cutaneous T-cell lymphoma.
    Bastidas Torres AN; Najidh S; Tensen CP; Vermeer MH
    Semin Cutan Med Surg; 2018 Mar; 37(1):81-86. PubMed ID: 29719024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-κB and nuclear factor of activated T cells pathways.
    Pérez C; Mondéjar R; García-Díaz N; Cereceda L; León A; Montes S; Durán Vian C; Pérez Paredes MG; González-Morán A; Alegre de Miguel V; Sanz Anquela JM; Frias J; Limeres MA; González LM; Martín Dávila F; Beltrán M; Mollejo M; Méndez JR; González MA; González García J; López R; Gómez A; Izquierdo F; Ramos R; Camacho C; Rodriguez-Pinilla SM; Martínez N; Vaqué JP; Ortiz-Romero PL; Piris MA
    Br J Dermatol; 2020 Jan; 182(1):147-155. PubMed ID: 31049933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside.
    Damsky WE; Choi J
    Curr Treat Options Oncol; 2016 Jul; 17(7):33. PubMed ID: 27262707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma.
    Yumeen S; Girardi M
    Yale J Biol Med; 2020 Mar; 93(1):111-121. PubMed ID: 32226341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications.
    Luna DE; Shinohara MM
    Curr Hematol Malig Rep; 2023 Jun; 18(3):83-88. PubMed ID: 37017872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic Silencing of Tumor Suppressor miR-124 Directly Supports STAT3 Activation in Cutaneous T-Cell Lymphoma.
    García-Colmenero L; González J; Sandoval J; Guillén Y; Diaz-Lagares A; Andrades E; Iglesias A; Nonell L; Pujol RM; Bigas A; Espinosa L; Gallardo F
    Cells; 2020 Dec; 9(12):. PubMed ID: 33333886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
    Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
    Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.
    Xu J; Huang H; Wang S; Chen Y; Yin X; Zhang X; Zhang Y
    Arch Dermatol Res; 2020 Sep; 312(7):513-525. PubMed ID: 31676945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expression of cell adhesion molecule 1 and its splicing variants in Sézary cells and cell lines from cutaneous T-cell lymphoma.
    Yamaguchi M; Morizane S; Hamada T; Miyake T; Sugaya M; Iwata H; Fujii K; Haramoto-Shiratsuki R; Nakagawa Y; Miura M; Ohshima K; Morishita K; Takahashi T; Imada M; Okada K; Uehara J; Sowa-Osako J; Iwatsuki K
    J Dermatol; 2019 Nov; 46(11):967-977. PubMed ID: 31515833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Localization of clonal T cells to the epidermis in cutaneous T-cell lymphoma.
    Fivenson DP; Hanson CA; Nickoloff BJ
    J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):717-23. PubMed ID: 7929915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma.
    Ralfkiaer U; Lindahl LM; Litman T; Gjerdrum LM; Ahler CB; Gniadecki R; Marstrand T; Fredholm S; Iversen L; Wasik MA; Bonefeld CM; Geisler C; Krejsgaard T; Glue C; Røpke MA; Woetmann A; Skov L; Grønbæk K; Odum N
    Anticancer Res; 2014 Dec; 34(12):7207-17. PubMed ID: 25503151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping signal transducer and activator of transcription (STAT) activity in different stages of mycosis fungoides and Sezary syndrome.
    Olszewska B; Żawrocki A; Lakomy J; Karczewska J; Gleń J; Zabłotna M; Malek M; Jankau J; Lange M; Biernat W; Nowicki RJ; Sokołowska-Wojdyło M
    Int J Dermatol; 2020 Sep; 59(9):1106-1112. PubMed ID: 32643174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell receptor gene rearrangement in canine mycosis fungoides: further support for a canine model of cutaneous T-cell lymphoma.
    Fivenson DP; Saed GM; Beck ER; Dunstan RW; Moore PF
    J Invest Dermatol; 1994 Feb; 102(2):227-30. PubMed ID: 7906287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
    Sibbesen NA; Kopp KL; Litvinov IV; Jønson L; Willerslev-Olsen A; Fredholm S; Petersen DL; Nastasi C; Krejsgaard T; Lindahl LM; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Iversen L; Bonefeld CM; Geisler C; Woetmann A; Odum N
    Oncotarget; 2015 Aug; 6(24):20555-69. PubMed ID: 26244872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes.
    Laharanne E; Oumouhou N; Bonnet F; Carlotti M; Gentil C; Chevret E; Jouary T; Longy M; Vergier B; Beylot-Barry M; Merlio JP
    J Invest Dermatol; 2010 Jun; 130(6):1707-18. PubMed ID: 20130593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cross-talk between miRNAs and JAK/STAT pathway in cutaneous T cell lymphoma: Emphasis on therapeutic opportunities.
    Patil K; Sher G; Kuttikrishnan S; Moton S; Alam M; Buddenkotte J; Ahmad A; Steinhoff M; Uddin S
    Semin Cell Dev Biol; 2024 Feb; 154(Pt C):239-249. PubMed ID: 36216715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma.
    Kamijo H; Miyagaki T; Shishido-Takahashi N; Nakajima R; Oka T; Suga H; Sugaya M; Sato S
    Blood; 2018 Nov; 132(18):1922-1935. PubMed ID: 30194255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
    Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
    Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.